Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.59 |
| ▸ | PRKACA | P17612 | 3/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.59 |
| ▸ | GSK3A | P49840 | 3/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.59 |
| ▸ | NEK4 | P51957 | 3/20 | 0.59 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.59 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.59 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.59 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.59 |
| ▸ | HIPK4 | Q8NE63 | 3/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.59 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.59 |
| ▸ | SGK2 | Q9HBY8 | 3/20 | 0.59 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024721 | 0.91 | CHEK1 (0.50) | CHEK1CHEK2PRKACARPS6KB1GSK3A | |
| SCHEMBL4026559 | 0.90 | GSK3A (0.62) | CHEK1CHEK2PRKACARPS6KB1GSK3A | |
| SCHEMBL4024345 | 0.87 | PRKACA (0.79) | CHEK1CHEK2PRKACARPS6KB1GSK3A | |
| SCHEMBL4024997 | 0.81 | FAAH (0.52) | CHEK1CHEK2PRKACARPS6KB1GSK3A | |
| SCHEMBL4028084 | 0.81 | FLT4 (0.60) | CHEK1CHEK2PRKACARPS6KB1GSK3A | |
| SCHEMBL4023522 | 0.80 | NAMPT (0.48) | CHEK1CHEK2PRKACARPS6KB1GSK3A | |
| SCHEMBL4026945 | 0.80 | NAMPT (0.48) | CHEK1CHEK2PRKACARPS6KB1GSK3A | |
| SCHEMBL4029995 | 0.80 | FLT4 (0.64) | CHEK1CHEK2PRKACARPS6KB1GSK3A | |
| SCHEMBL4026710 | 0.79 | PRKACA (0.65) | CHEK1CHEK2PRKACARPS6KB1GSK3A | |
| SCHEMBL5753737 | 0.78 | PRKACA (0.56) | CHEK1CHEK2PRKACARPS6KB1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | claimed |
| EP-1674457-B1 | Derivatives of squaric acid with anti-proliferative activity | GPC BIOTECH AG (DE) | 2009-06-03 | — | — | EP | claimed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | claimed |
| EP-1674457-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2096107-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1674457-B1 | Derivatives of squaric acid with anti-proliferative activity | GPC BIOTECH AG (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
| EP-1674457-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | SQLE, FDFT1, DLD | CHEK1 2465/4885CHEK2 2740/4885PRKACA 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.